A total of 103 individuals with immunotherapy for metastatic melanoma were randomly distributed into training (n?=?69) and validation cohort (n?=?34) in order to recognize predictive clinical and CT imaging biomarkers and evaluate their predictive capability about overall survival (OS) and treatment response in individuals with metastatic melanoma who were undergoing immunotherapy.
Publications
European Commission Approves 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma
The European Commission has approved nivolumab (Opdivo) at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.1
MRV Newletter Issue 11, November 2019
Please follow this link to download the 11th edition of the MRV newsletter.
Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma
NEW YORK – Taiwanese cancer diagnostic firm ACT Genomics said on Monday that it has launched a study in collaboration with the University of California, San Diego Moores Cancer Center that will evaluate gene expression signals associated with the tumor microenvironment that may predict outcome in melanoma patients treated with PD-1 inhibition.